US 12,441,739 B2
Glucagon receptor antagonist and use thereof
Qifeng Bai, Shenzhen (CN); Tingyang Xu, Shenzhen (CN); Liya Feng, Shenzhen (CN); Shuo Liu, Shenzhen (CN); Junzhou Huang, Shenzhen (CN); Huanxiang Liu, Shenzhen (CN); and Xiaojun Yao, Shenzhen (CN)
Assigned to LANZHOU UNIVERSITY, Lanzhou (CN); and TENCENT TECHNOLOGY (SHENZHEN) COMPANY LIMITED, Shenzhen (CN)
Filed by LANZHOU UNIVERSITY, Lanzhou (CN); and TENCENT TECHNOLOGY (SHENZHEN) COMPANY LIMITED, Shenzhen (CN)
Filed on Dec. 5, 2022, as Appl. No. 18/074,889.
Application 18/074,889 is a continuation of application No. PCT/CN2022/076637, filed on Feb. 17, 2022.
Claims priority of application No. 202110194113.X (CN), filed on Feb. 20, 2021.
Prior Publication US 2023/0104956 A1, Apr. 6, 2023
Int. Cl. C07D 495/04 (2006.01); A61P 3/10 (2006.01)
CPC C07D 495/04 (2013.01) [A61P 3/10 (2018.01)] 20 Claims
 
1. A compound represented by the following structural formula A, or a stereoisomer , pharmaceutically acceptable ester, or pharmaceutically acceptable salt thereof,

OG Complex Work Unit Chemistry
wherein R1 is H, F, Cl, Br, or I;
R2 is H or —O—(CH2)m—CH3, m being an integer of 0-2;
R3 is H or —S—(CH2)n—CH3, n being an integer of 0-2; and
R4 and R5 together form

OG Complex Work Unit Chemistry
wherein the point of attachment for the sulfur atom is at the R5 position.